We performed global RNA transcript analysis and comprehensive gene group analysis of peripheral blood leukocyte (PBL) RNA from two groups of matched sib-pairs that were discordant for either schizophrenia (n ¼ 33 sib-pairs) or bipolar disorder (n ¼ 5 sib-pairs). The pairs chosen for these analyses were selected from families with known patterns of genetic linkage (5q for schizophrenia and 6q for bipolar disorder). At the single gene level, we obtained lists of the transcripts with the most significant changes in expression and from these lists determined those with the highest degree of predictive power for classifying subjects according to diagnosis in these samples. At the gene group level, we comprehensively analyzed pairwise expression changes of more than 4,000 functional groups and cytogenetic locations, and present a novel method of displaying these data that we term ''cytogenomic'' mapping. Verification of selected changes in expression was performed using quantitative real-time RT-PCR. Our results provide compelling evidence for the utility of analyzing PBL RNA for changes in expression in neuropsychiatric disorders.
INTRODUCTION
We have recently reported strong suggestive genomewide linkages for both schizophrenia and bipolar disorder in pedigrees from the Portuguese Island Collection [PIC; see Pato et al., 2004; Sklar et al., 2004] . In a follow-up study of bipolar disorder using a denser SNP-based genotyping method, we achieved genome-wide significance for linkage at 6q22 [Middleton et al., 2004] . In schizophrenia, the peak linkage signals were obtained on chromosome 5q31-35. In order to help expedite the selection of candidate genes in these (and other) regions, we have implemented a strategy involving the measurement of changes in gene expression in peripheral blood leukocytes (PBLs) in discordant sib-pairs from the two pedigree sets.
The analysis of mRNA transcript levels in PBLs from living subjects offers several advantages compared with studies involving only end point postmortem tissue specimens. Such advantages include the ability to completely match subject characteristics such as age, gender, family background, time of blood draw, geographical/environmental variables, diet, and the cellular composition of the samples. Moreover, it also becomes feasible to design studies that examine expression profiles of PBLs during the progression of the disease, or in response to drug treatments. These gene expression patterns, when obtained in well-controlled studies, have increased the power to help refine candidate gene selection for mutational screening, as well as obtain lists of genes with predictive power for classifying different diseases and their treatment response. Indeed, in the cancer field, it has become standard practice at some clinics that specialize in childhood leukemias to compare the expression profiles of PBLs or lymphocytes on all patients. These expression patterns not only correctly subtype the leukemia, but also serve as highly accurate predictors of the disease course [e.g., Yeoh et al., 2002] .
In neuropsychiatric diseases, no studies to date have been published on the potential utility of gene expression profiling of PBLs for either diagnosis or disease characterization. There has been, however, at least one study to date examining the gene expression profile of transformed lymphoblasts from a small number of subjects with schizophrenia in a single pedigree, which showed promising results [Vawter et al., 2004] . In the present, study, we wished to determine the changes in gene expression in a larger sample involving 33 sib-pairs from families segregating for schizophrenia from the PIC population where we had detected strong linkage to 5q. In addition, we performed a highly focused analysis of gene expression alterations in five sib-pairs from specific PIC families segregating for bipolar disorder that had linkage to 6q22. Our aims were to determine if this approach would have diagnostic utility and also help identify candidate genes with abnormal expression patterns in the regions that display significant linkage. Importantly, we have not assumed a priori that the changes in transcript levels that occur in PBLs necessarily indicate that similar patterns of expression alterations will be evident in the brains of subjects with schizophrenia or bipolar disorder. Rather, we merely hypothesized that if underlying genetic abnormalities altered transcript expression in a consistent manner, we would be able to detect such effects if the transcript was expressed in PBLs.
We suggest that such changes, when present, may reflect primary pathogenetic mechanisms, or simply conserved pathophysiological features of the illness or its treatment.
METHODS

Subject Ascertainment
Methods for subject ascertainment and classification are the same as previously described . Families with two or more affected individuals were ascertained from systematic screening of all treating clinicians, treatment facilities, social services, and extensive family interviews. In the Azores, all four psychiatric hospitals and the two general hospitals participated in the study. Similarly in Madeira, both psychiatric hospitals and the general hospital participated. On the mainland, families were identified by our collaborators at the University of Coimbra. Informed consent was obtained in writing from all subjects for participation in the genetic and family studies. Collection of blood and family history information was approved by all of the appropriate Institutional Review Boards. Best estimate diagnoses according to DSM-IV were made by two independent blinded researchers. All cases, where there was disagreement, were reviewed by a third senior psychiatrist blind to the status of the case (MT Pato, MD).
The specific subjects for this study were selected as genderand age-matched discordant sibs from families that participated in our linkage studies. For studies of schizophrenia, 40 such sib-pairs were selected from all families segregating for schizophrenia from the PIC population where we had detected strong linkage to 5q and had cell samples available for RNA purification. For bipolar disorder, we performed a highly focused analysis of gene expression alterations in five sib-pairs from specific PIC families segregating for bipolar disorder with linkage to 6q22. These 45 age-and gender-matched sib-pairs were screened for alterations in white blood cell composition (see below), which eliminated five schizophrenia sib-pairs from further consideration. After processing all arrays, a priori quality control criteria (excessive 3 0 /5 0 ratios for beta actin and GAPDH, and/or scale factors exceeding 10.0 for any subject) led us to eliminate two additional sib-pairs from our analyses. Thus, in total, 33 sib-pairs were used for our schizophrenia studies and five sib-pairs for our bipolar studies. To achieve the highest level of subject matching and quality control, we found it helpful to examine cellular composition using differential white blood cell counts (Wright's stain method). All of the samples included in this report had normal blood count differentials. The specific age and blood cell composition values for the schizophrenic group are the same as previously described ; 22 female pairs, 11 male pairs; mean ages AE SD of affecteds and unaffecteds ¼ 44.8 AE 12.4 and 42.8 AE 12.9, respectively; mean neutrophil counts ¼ 58.9 AE 4.8% and 56.8 AE 4.7%; mean lymphocyte counts ¼ 34.1 AE 7.0% and 33.9 AE 4.2%). For the bipolar subject pairs, the mean values AE SD for affecteds and unaffecteds was age ¼ 41.2 AE 5.8 and 40.8 AE 11.4; neutrophils ¼ 55.4 AE 4.4, 59.2 AE 2.9; lymphocytes ¼ 38.4 AE 4.7, 35.2 AE 2.8. There were no significant pairwise or unpaired differences between the subject groups and the matched controls for any of these values.
Microarray Gene Expression Sample Preparation
Total RNA was extracted from leukocyte cell preparations from 66 siblings selected from the 40 schizophrenia pedigrees used in a previous linkage study [see Sklar et al., 2004] and 10 siblings selected from the 25 bipolar pedigrees used in a previous linkage study [see Middleton et al., 2004] . Total RNA quality and quantity was assessed using UV spectrophotometry and comparison of 28S:18S ratios with the Bioanalyzer RNA Nano Chip (Agilent). Microarray samples were labeled and processed according to standard protocols, hybridized to the Human Genome U133A GeneChipß (Affymetrix), washed and stained on a fluidics station (Affymetrix) according to the EukGE-WS2 protocol, and scanned using the G2500A Gene Array Scanner. The scan files were normalized using the Gene Chip Robust Multichip Analysis method [Irizarry et al., 2003] . Statistical changes in gene expression were determined in pairwise fashion using the Significance Analysis algorithm (GeneTraffic, Iobion). All of the transcript probes that were significantly changed (P < 0.05) were ranked by mean pairwise fold change. This was applied to both the entire genome for schizophrenia and bipolar disorder (Tables I and II , respectively) and each of the candidate genome regions (5q and 6q) (Table III) . Notably, because of the relatively small number of sib-pairs used in the bipolar study, we present the top fold changes in the 6q locus using a threshold of P < 0.10 for this disorder.
Prediction Classification
From the lists of significantly changed genes, we also sought to derive a preliminary list of genes whose expression patterns might be useful as predictors of diagnosis. For this analysis, we used the Class Predictor algorithm (GeneSpring) to predict the value, or ''class,'' of individual parameters in the set of samples. This was done using both the Euclidian nearest neighbor method and support vector machine (SVM) method. The genes with the highest predictive power in our dataset were ranked by their predictive strength (Table IV) . Importantly, we point out that because we used the methods that require defining a training set, the list we present still requires validation in an independent cohort.
Gene Group Analysis
We determined the relevant biological pathway information in our expression data using custom-written software [PathStat; see Middleton et al., 2004 ] to extract distributions of differential expression ratios for functionally related groups of transcripts using publicly curated databases. These databases included the different groups of the Gene Ontology database (http://us.expasy.org/cgi-bin/enzyme-search-cl), the Kyoto Encyclopedia of Genes and Genomes database (http:// www.genome.ad.jp/kegg/pathway.html), the Enzyme Commission database (http://us.expasy.org/cgi-bin/enzyme-search-cl), and the Protein Family (pFam) database (http://www.sanger. ac.uk/Software/Pfam/search.shtml). Lists of the specific probes on the Affymetrix U133A GeneChip that belong to each of these groupings are available in a single annotated file from the Affymetrix NetAffx website (http://www.affymetrix.com/ support/technical/byproduct.affx?product¼hgu133-20). To perform the pathway analyses, the scaled and normalized gene expression level was first calculated using robust multi-chip analysis (RMA), and then the expression level of each gene in the affected pairs (BP or SCZ subjects) was compared to the corresponding expression level of the same gene in the matched control subject. This ratio was generated only if the expression level in at least one of the samples was greater than the median RMA normalized signal intensity of the dataset (computed signal $12 or higher). PathStat then compiled the gene-bygene expression ratios for each functional group, as well as all the genes on the chip, and calculated a t statistic for the group that was proportional to the number of standard deviations that group's expression had shifted in the affected subject pair, adjusted for the number of transcripts in each group. Gene group ratios were only generated if an average of at least three transcript ratios were computed in each group [Middleton et al., 2002 [Middleton et al., , 2004 . For each disease, we present the omnibus data (all 5 or 33 subject pairs combined) for this report. This highly conservative method enables one to detect large-scale coordinated changes in functional gene group expression in complex treatment paradigms or disease states. In the present analysis, PathStat mapped our expression data to a total of more than 3,000 separate publicly curated pathways. Tables of the top 25 increased and decreased gene group alterations in each disorder were generated.
Cytogenomics
In addition to the functional gene groups, we also utilized a new approach for mining and mapping expression changes within the context of cytogenetic loci, an approach we term ''cytogenomics.'' For example, single megabase bins generally contain approximately 8-12 gene probes of which approximately half will be expressed in the blood or brain of human subjects. Each of these megabase bins was treated as a gene group cluster and the pairwise and genewise differences in expression used to create high-density cytogenomic Z score plots (Fig. 1) . These Z score plots were compared directly with the NPL Z score plot and a Chi Square plot derived from the linkage and association analyses of schizophrenia and bipolar disorder. Two examples of the utility of this approach are provided (Fig. 2) . To perform the genome-wide association analysis, we used Varia (Silicon Genetics) to construct a haplotype map (E-M algorithm) of the complete set of 25 bipolar families genotyped with the Affymetrix Human Mapping Assay Xba 141 [see Middleton et al., 2004] . A preliminary genome-wide family-based Transmission Disequilibrium Test (TDT) was performed and the most significant results for the entire genome were listed (Table VIII) . Moreover, the Chi Square values from this analysis were overlaid with the expression and linkage plots for chromosome 6q (Fig. 2) .
Microarray Validation With Quantitative
Real-Time RT-PCR (qRT-PCR)
Validation of selected changes in expression was performed using quantitative real-time RT-PCR (qRT-PCR), using RNA from 19 of the 33 schizophrenia sibpairs and all 5 bipolar sibpairs for whom sufficient RNA was available. Primer sequences for each gene of interest were designed using Primer3 software, and are available upon request. For the RT reactions, equal amounts of total RNA (250 ng) from each sample were reverse transcribed (Superscript II protocol) with an oligo dT primer prior to quantitative PCR according to the standard TaqMan protocol (Applied Biosystems) using SYBRGreen I dye for amplicon detection with an ABI-7000 Real Time Sequence Detection System (Applied Biosystems). Statistical analysis was performed using a pairwise repeated measures ANOVA comparing the difference in the number of cycles to threshold (DCt) between each target gene and alpha tubulin. Group differences were calculated by determining the mean pairwise difference in the delta Ct values per subject group (the DDCt), and a fold change calculated according to the formula, Fold change ¼ 2 ÀDDCt .
RESULTS
Sib-Pair Analyses
Global significance analysis. Of the 22,283 probe sets on the array, in a strict pairwise analysis with the RMA normalized data, more than 2,000 genes showed significant changes in expression in our schizophrenia sib-pairs and 248 genes showed significant changes in expression in our much smaller set of bipolar sib-pair data (P < 0.05). Given the larger number of samples used in the schizophrenia analysis, implementing a multiple testing correction (BenjaminiHochberg) still produced a list of approximately 300 genes with significant changes in expression. However, because such a correction in P-values was not possible with the much smaller bipolar dataset, we chose to present purely uncorrected P-values in this report. The 40 genes with the most robust increases and decreases in expression among those that were significantly affected are shown for each disorder (Tables I and II) . While the limited sample size does not allow us to make specific comments on each of the genes in these tables, we have decided to present these data in order for other groups that may be working on similar efforts to be able to compare (and potentially combine) their findings with ours. We do point out that several of the genes with the most significant changes in expression did not exhibit large enough alterations to be included in these tables, which are based purely on fold changes.
Targeted significance analysis. We identified 729 transcript probes on the U133A GeneChip that were localized to 5q for use in analyzing our SCZ sib-pairs and 431 transcripts on 6q that were used to analyze expression in our BP sib-pairs. The 14 genes showing the largest fold changes (increases or decreases) at each locus were shown using a P-value threshold of 0.05 for schizophrenia and 0.10 for bipolar disorder (Table III) .
Prediction classification. We used the Class Predictor Algorithm to identify those genes with the greatest potential diagnostic utility in schizophrenia and bipolar disorder in this population. After optimization, the nearest neighbor algorithm produced a list of 35 transcripts with approximately 95% accuracy. Overall, 70 of 76 subjects were correctly classified as a control, BP or SCZ subject based on sib-pair expression differences, with four subjects misclassified and two subjects not classified. The SVM method obtained 100% accuracy with as few as 10 genes. The list of transcripts in both of these respective classifier lists was nearly identical. For simplicity, we present the top 50 predictor genes, ranked by their predictive strength according to the SVM algorithm (Table IV) .
Gene group analysis. We assessed the expression patterns of all publicly curated functional pathways that could be mapped to the U133A GeneChip content. This analysis of more than 3,000 unique transcript collections revealed a set of gene groups with robust changes in expression in each disorder (Table V) . Extending this analysis to include groups of genes located at the same physical position (in 1-MB bins), indicated fairly strong expression changes in a number of key loci in each disorder (Table VI) . Importantly, we note that the Z scores for the top affected loci in each disorder were not correlated in the BP and SCZ datasets.
Cytogenomic mapping of expression abnormalities. The binning of the data used in the Gene Group Analysis allowed us to create Z score maps of the pairwise expression changes in our datasets, which we plotted for comparative purposes in a manner similar to a whole genome screen (Fig. 1) . We point out that this figure revealed considerably different cytogenomic profiles for these two disorders. For illustrative purposes, we have also chosen to display the potential overlap of genetic and functional genomic signals on chromosomes 5q for schizophrenia and 6q for bipolar disorder (Fig. 2) . This side by side analysis revealed a fair amount of overlap in the genetic linkage, association, and functional genomic results as was suggested by the data (Table VI) .
Family-based association. Analysis of haplotype-based TDT performed by Varia using the 25 bipolar family dataset revealed a number of genomic regions with nominally significant linkage disequilibrium (Table VII) . Despite the limits of the resolution of the SNP map used to generate haplotypes ($210 KB), it is notable that several of the haplotype blocks highlighted are located in proximity to both the 6q linkage peak and the gene expression Z score peaks. We have begun to use higher density SNP genotyping arrays to achieve greater resolution and explore these intriguing findings in more detail.
Validation of selected genes with real-time quantitative RT-PCR. In our PBL sib-pairs, we examined the expression of multiple individual transcripts with an independent technique to confirm the accuracy and reliability of the microarray data. Due to limited RNA, only 19 of the original 33 schizophrenic sib-pairs (but all 5 bipolar sib-pairs) were used in these studies. Several genes with increased and decreased expression, including the Sensory and Motor Neuron Derived Factor (SMDF) variant of Neuregulin 1 (NRG1), Transcription factor-like 4 (TCFL4), Serotonin Receptor Type 4 (5HT4), and A Disintegrin and Matrix Metalloproteinase 19 (ADAM19) were all confirmed as showing the same (or greater) amount of Fig. 1 . Cytogenomic plot of expression abnormalities by MB. To generate this map, the pairwise differential expression ratio distribution of all expressed transcripts within 1 MB proximity was determined, and the relative shift in this ratio distribution that compared the entire genome was calculated (as a Z score). For simplification, only the absolute value of the Z score is shown for each disorder. We note that SCZ and BP data do not display much similarity in their cytogenomic patterns.
change seen in the array data (Table VIII) . A fifth transcript (Synaptobrevin 2, or VAMP2) was confirmed as showing the same direction of change as the array data, but the P-value did not attain significance (Table VIII) . Moreover, other genes that did not change in the array data were also confirmed, including at least two housekeeping genes-alpha tubulin and RNA Polymerase II (Table VIII) . Overall, the mean pairwise fold changes for these seven transcripts were highly correlated in the array and PCR datasets (R ¼ 0.951).
Genes involved in presynaptic function in the brain are also altered in PBLs. Expression profiling of postmortem brain tissue in subjects with schizophrenia has revealed some commonly affected intracellular cascades, particularly those involving presynaptic secretory function [PSYN genes; see Mirnics et al., 2000] . In order to begin to address whether PBLs also share some of the same expression changes as postmortem brain, we searched for significant (P < 0.05) pairwise expression changes in the PSYN genes in our schizophrenia data. Interestingly, some 35 unique transcripts were found with such changes. Most of these involved small differences (less than 20% mean pairwise changes). However, among the transcripts with 20% or greater increases in expression were synaptophysin-like protein (SYPL, þ1.4-fold), synaptosomal-associated protein, 23 kDa (SNAP23, þ1.4-fold), N-ethylmaleimide-sensitive factor (NSF, þ1.4-fold), dynactin 3 (DCTN3, þ1.4-fold), sorting nexin 2 (SNX2, Fig. 2 . Regions of putative genetic and functional genomic convergence. Top, Nonparametric linkage results in families used in a medium resolution microsatellite scan of chromosome 5q . Data have been replotted in physical (MB) coordinates (dashed line). The pairwise gene expression data from 33 discordant sib-pairs from these families were used to generate an expression Z score plot through the same region (solid line). Bottom, Families with 6q22 linkage from the 25 used in a previous genomewide screen [dashed line; Middleton et al., 2004] were analyzed with a highdensity SNP genotyping array. The data from this same dataset were used to create a whole genome haplotype map and test for TDT. The Chi Square values obtained in the TDT analysis for chromosome 6q are illustrated (dotted line). Five age-and gender-matched discordant sib-pairs from these families were used for leukocyte expression analysis in the current study (expression Z score as solid line). We note that the peak expression Z scores in both schizophrenia and bipolar disorder are located near peak linkage regions, although the positions of the TDT peaks show even more similarity with the expression Z score peaks. þ1.3-fold), vacuolar protein sorting 33B (VPS33B, þ1.3-fold), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta (YWHAB, þ1.2-fold), and vesicle-associated membrane protein 4 (VAMP4, þ1.2-fold). On the other hand, far fewer PSYN transcripts showed pairwise decreases in expression of this magnitude, with the notable exceptions of clathrin, heavy polypeptide (CLTC, -1.2-fold) and synaptojanin 2 (SYNJ2, À1.2-fold). These findings of increased expression of NSF, synaptophysin, and other related genes are actually opposite the findings reported in previous microarray studies of postmortem brain tissue. Taken together, these observations reinforce the potential power of PBL expression data to detect significant expression alterations of some of the same genes implicated by postmortem brain tissue studies, although the direction of change is not necessarily the same.
DISCUSSION
In this very preliminary study, we have explored the potential utility of gene expression data acquired from PBLs of subjects with schizophrenia or bipolar disorder and their discordant age-and gender-matched siblings. Specifically, we sought to: (1) identify those genes and functional gene groups that are the most affected in the disease (pathophysiogenomics); (2) evaluate candidate genes and gene regions for abnormal expression patterns that are correlated with known locations of genetic linkage or association in the same population; (3) identify genes with the greatest degree of diagnostic utility; (4) search for candidate genomic loci that might be involved in the primary disease pathogenesis; and (5) attempt to correlate specific SNP haplotypes with altered expression patterns. We briefly highlight some of our progress in each of these aims.
Most Significantly Changed Genes in Schizophrenia and Bipolar Disorder
It is not possible for us to review all of the single gene findings in our dataset within the context of this preliminary report. Thus, we have chosen to highlight a few of the observations that we believe have particular novelty or relate to the preexisting literature on schizophrenia, bipolar disorder, or brain function.
Schizophrenia. There were a number of genes among those with the most significant increases in expression that are known to be involved in immune and/or inflammatory function (e.g., CD14 antigen, chemokine receptor 1; Table I) . Interestingly, however, we also detected a number of expression changes in genes that are known to be involved in brain development (e.g., alpha catenin, neuregulin 1 (SMDF variant)). The single most significantly affected gene was TCFL4, which was 1.42-fold decreased, P ¼ 0.0003), but did not achieve a magnitude large enough to be listed in Table I . This gene is also known as MAX-like protein (or MLX). We also highlight the increase in expression of transducer of ERBB2, 2 (TOB2, 1.65-fold increased, P ¼ 0.00014) ( Table I ). The change in TOB2 is noteworthy because this gene is located in close proximity to a schizophrenia susceptibility locus (22q13) and because of the alteration in expression we observed for neuregulin 1, SMDF (sensory and motor neuron derived factor) variant. TOB2 is a transducer of the tyrosine kinase receptors from the ErbB family, which also exert control over NRG signaling. The role of NRG is critical to early development of the central nervous system and includes stimulation of Schwann cell growth as well as generation of acetylcholine receptors at the neuromuscular synapse [reviewed in Falls, 2003] . Of the seven splice variants of NRG on the array, only the SMDF variant has altered gene expression in schizophrenic subjects versus controls. A full report on these findings was recently reported elsewhere . Together, our data support further examination of the role of NRG signaling in schizophrenia. Bipolar disorder. Among the genes with the most consistent and significant changes in expression was one not previously reported in bipolar disorder, termed MAX (1.94-fold increase, P ¼ 0.015; Table II ). The finding regarding increased MAX expression in bipolar disorder is particularly interesting in light of the increased expression of TCFL4/MLX in schizophrenia. The MAX gene encodes for a member of the basic region-helix-loop-helix-zipper proteins [Gilladoga et al., 1992] . The MAX protein has been shown to associate with N-, L-, and c-myc proteins [Gilladoga et al., 1992] and other proteins and transcription factors, such as TCFL4. It has been found that TCFL4 works in conjunction with ChREBP (carbohydrate response element-binding protein) to regulate the expression of genes responsive to glucose [Stoeckman et al., 2004] . Interestingly, we also observed a number of transcripts involved in G protein signaling to exhibit altered expression in bipolar disorder (e.g., guanine nucleotide binding protein (G protein), beta polypeptide 1; G protein-coupled receptor kinase 5; Table II ). Collectively, these data suggest there are prominent changes in cellular transduction mechanisms in this illness.
Functional Gene Group Alterations
Through the use of custom-written software, we were able to analyze the expression patterns of entire groups of genes that perform the same function in cells. The basis and utility of All expression peaks noted exceeded a Z score of 1.6 and were within 10 MB of the TDT peak.
this approach has been reviewed previously [Middleton et al., 2002 [Middleton et al., , 2004 . In the present dataset, we have obtained evidence that several major biological pathways related to lipid and fatty acid metabolism are decreased in bipolar disorder (e.g., sterol transporter, long-chain-fatty-acid-CoA ligase, and cholesterol metabolism; Table VI ). In the schizophrenia dataset, these same gene groups were not changed, although the group apolipoprotein A1/A4/E family was similarly decreased (Table VI) . Interestingly, among the most increased gene groups in bipolar disorder was the group containing transcripts of the Ezrin family. Ezrin interacts with actin to stabilize uptake process (including the uptake of cholesterol), and has been shown to be important in neurite outgrowth during cortical formation. Ezrin itself is not apparently expressed in neurons, but is abundant within radial glia and migrating cells in the intermediate zone [Johnson et al., 2002] . Together, these data suggest that subjects with schizophrenia and bipolar disorder both exhibit alterations of molecules involved in fatty acid and lipid metabolism that are vital to normal brain function, although the specific genes showing the greatest changes are distinct for each disorder.
Classification by Gene Expression
We tested the ability of our dataset to correctly distinguish subjects with schizophrenia or bipolar disorder from their unaffected discordant sibs using the nearest neighbor class predictor algorithm (GeneSpring). An iterative approach was used to determine the number of genes and gene neighbors that produced the highest accuracy. The use of 35 potential candidates and 7 nearest neighbors successfully classified 70 of 76 subjects in accordance with their true diagnosis (i.e. unaffected, BP or SCZ).
Of the six misclassified or unclassified subjects, three SCZ patients were classified as BP, one SCZ was misclassified as unaffected, and two subjects were not classified. Thus, in its initial training set, the algorithm had an accuracy of classification of 87% for schizophrenia (27 of 31 correct diagnoses) and 89% for the combined SCZ and BP subject sets (32 of 36 correct diagnoses). We wish to stress that the small number of BP subjects used in this study likely contributed to a less distinct predictor gene set being obtained for this disease. Interestingly, only one patient was misclassified as an unaffected subject. Moreover, two of the subjects with schizophrenia that were classified as probable bipolar subjects actually had family histories of bipolar disorder and/or carried a Best Estimate Diagnosis of schizoaffective disorder. By convention, schizoaffective disorder, depressed has been considered affected in schizophrenia linkage studies and schizoaffective disorder, bipolar has been considered affected in bipolar linkage studies. This convention may promote confounds that would limit the ability of gene expression profiling. For example, if we eliminate those schizoaffective subjects that were classified as schizophrenics in our linkage studies, three of the four classification errors would be removed. This would increase the diagnostic accuracy to 96% (27 of 28 correct). Although preliminary, this observation highlights the need for careful evaluation of the nature of schizoaffective disorder and the use of these patients as part of the core phenotype definition. In addition to the nearest neighbor method, we also obtained 100% accurate classification using a SVM model with our gene expression data. Most of the genes with the highest predictive strength were the same for these two methods, and are listed in Table IV . Notably, several of these predictor genes are located on the loci of interest (e.g., alpha catenin) or have been previously mentioned (e.g., TCFL4).
Cytogenomic Mapping of Expression Data Compared to Linkage/LD Data
Our method of analyzing the expression of groups of genes in close physical proximity (cytogenomics) has provided clear examples where the abnormalities converge with the loci identified through linkage and/or association screening. Despite the clear limitations of this preliminary study, our results support the potential utility of this multifaceted approach to the study of neuropsychiatric illness. Based on this approach, however, we have already extended these results to specifically test candidate genes within the 5q linkage region in schizophrenia that displayed abnormal expression patterns and found significant relationships to haplotype-linkage disequilibrium in the same region .
CONCLUSIONS
Overall, we find that screening of gene expression patterns in PBLs of subjects with schizophrenia or bipolar disorder shows potential both in terms of diagnostic utility as well as revealing new biological insights into these disorders. Much of the data we are accumulating point toward alterations of specific loci and specific biological pathways in each illness. We recognize the need for follow-up studies of our results. Nonetheless, the data we present provide a framework for our ongoing research and allow other groups to test specific hypotheses in their datasets.
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